These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1926772)

  • 1. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease.
    Von Gegerfelt A; Albert J; Morfeldt-Månson L; Broliden K; Fenyö EM
    Virology; 1991 Nov; 185(1):162-8. PubMed ID: 1926772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
    Albert J; Abrahamsson B; Nagy K; Aurelius E; Gaines H; Nyström G; Fenyö EM
    AIDS; 1990 Feb; 4(2):107-12. PubMed ID: 2328092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates.
    Devico A; Silver A; Thronton AM; Sarngadharan MG; Pal R
    Virology; 1996 Apr; 218(1):258-63. PubMed ID: 8615032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
    Tsang ML; Evans LA; McQueen P; Hurren L; Byrne C; Penny R; Tindall B; Cooper DA
    J Infect Dis; 1994 Nov; 170(5):1141-7. PubMed ID: 7963706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals.
    von Gegerfelt A; Chiodi F; Keys B; Norkrans G; Hagberg L; Fenyö EM; Broliden K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1133-8. PubMed ID: 1503825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses.
    Nyambi PN; Nkengasong J; Peeters M; Simon F; Eberle J; Janssens W; Fransen K; Willems B; Vereecken K; Heyndrickx L
    J Infect Dis; 1995 Nov; 172(5):1228-37. PubMed ID: 7594658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS.
    Scarlatti G; Leitner T; Hodara V; Jansson M; Karlsson A; Wahlberg J; Rossi P; Uhlén M; Fenyö EM; Albert J
    Immunol Lett; 1996 Jun; 51(1-2):23-8. PubMed ID: 8811340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
    Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC
    J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a primary isolate-like virus from simian and human immunodeficiency virus-infected macaque having broad neutralizing activity.
    Miyazaki Y; Kuwata T; Takehisa J; Hayami M
    AIDS Res Hum Retroviruses; 2002 Apr; 18(6):469-75. PubMed ID: 11958690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.
    Beaumont T; Broersen S; van Nuenen A; Huisman HG; de Roda Husman AM; Heeney JL; Schuitemaker H
    J Virol; 2000 Sep; 74(17):7699-707. PubMed ID: 10933675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.
    Tremblay M; Wainberg MA
    J Infect Dis; 1990 Sep; 162(3):735-7. PubMed ID: 2387997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.
    Tóth FD; Szabó B; Ujhelyi E; Pálóczi K; Horváth A; Füst G; Kiss J; Bánhegyi D; Hollán SR
    AIDS; 1991 Mar; 5(3):263-8. PubMed ID: 1676275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.